"Rifampin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)
| Descriptor ID |
D012293
|
| MeSH Number(s) |
D03.633.400.811.700 D04.345.295.750.700
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Rifampin".
Below are MeSH descriptors whose meaning is more specific than "Rifampin".
This graph shows the total number of publications written about "Rifampin" by people in this website by year, and whether "Rifampin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 0 | 1 | 1 |
| 2006 | 1 | 0 | 1 |
| 2008 | 2 | 1 | 3 |
| 2009 | 1 | 0 | 1 |
| 2010 | 1 | 1 | 2 |
| 2011 | 3 | 2 | 5 |
| 2012 | 2 | 2 | 4 |
| 2013 | 1 | 1 | 2 |
| 2014 | 0 | 2 | 2 |
| 2015 | 4 | 3 | 7 |
| 2016 | 6 | 2 | 8 |
| 2017 | 4 | 3 | 7 |
| 2018 | 6 | 3 | 9 |
| 2019 | 5 | 5 | 10 |
| 2020 | 1 | 4 | 5 |
| 2021 | 4 | 13 | 17 |
| 2022 | 0 | 9 | 9 |
| 2023 | 0 | 8 | 8 |
| 2024 | 4 | 2 | 6 |
| 2025 | 3 | 0 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Rifampin" by people in Profiles.
-
Efficacy and Safety of 4-Month Rifapentine-Based Tuberculosis Treatments in Persons with Diabetes. Emerg Infect Dis. 2025 Mar; 31(3):467-476.
-
Characteristics of children and adolescents with multidrug-resistant and rifampicin-resistant tuberculosis and their association with treatment outcomes: a systematic review and individual participant data meta-analysis. Lancet Child Adolesc Health. 2025 Feb; 9(2):100-111.
-
24-week, all-oral regimens for pulmonary rifampicin-resistant tuberculosis in TB-PRACTECAL trial sites: an economic evaluation. Lancet Glob Health. 2025 Feb; 13(2):e355-e363.
-
Risk factors for and timing of presumptive recurrent TB. Int J Tuberc Lung Dis. 2024 Nov 01; 28(11):527-533.
-
Long-term efficacy and safety of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): extended follow-up of an open-label, multicentre, randomised, non-inferiority trial. Lancet Respir Med. 2024 Dec; 12(12):975-987.
-
Influence of age and co-medication on dolutegravir glucuronidation in paediatric patients. Br J Clin Pharmacol. 2024 Nov; 90(11):2947-2952.
-
Accuracy of cobas MTB and MTB-RIF/INH for Detection of Mycobacterium tuberculosis and Drug Resistance. J Mol Diagn. 2024 Aug; 26(8):708-718.
-
Target regimen profiles for tuberculosis treatment. Bull World Health Organ. 2024 Aug 01; 102(8):600-607.
-
Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trial. Lancet Infect Dis. 2024 Sep; 24(9):1003-1014.
-
Organisation of care for people receiving drug-resistant tuberculosis treatment in South Africa: a mixed methods study. BMJ Open. 2023 11 17; 13(11):e067121.